NCT06412198 2026-03-06
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
M.D. Anderson Cancer Center
University of Wisconsin, Madison
Grey Wolf Therapeutics
Maastricht University Medical Center
AHS Cancer Control Alberta
University Medical Center Groningen
Icahn School of Medicine at Mount Sinai
Dana-Farber Cancer Institute
Vanderbilt-Ingram Cancer Center